Although there are many reports about therapies for DAH in SLE that include cyclophosphamide, plasmapheresis, extracorporeal membrane oxygenation (ECMO), rituximab, mycophenolate mofetil, recombinant factor VII, and stem cell transplantation, they are general immune suppression or salvage therapies (Kazzaz et al, 2015). This evidence concerns the gene F7 and systemic lupus erythematosus.